Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 26, 2024Journal of Clinical MedicineOpen Access

Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMatteo MegnaABAnna BalatoSCStefano Caccavale

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Megna et al. (2024) studied this question.

synapsesocial.com/papers/68e6d58fb6db643587652d97https://doi.org/10.3390/jcm13092552
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study2024 · 9 citations
  2. 2Guselkumab effectiveness in real world settings: observations from an Italian multi-center study2025 · 2 citations
  3. 3The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study2024 · 10 citations
  4. 44CPS-085 Long-term persistence in psoriasis patients with high response to guselkumab: a real-world retrospective study2024
  5. 5Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study2024 · 6 citations